Needle free: Erase wrinkles without injection
Meet REVOLUTION BEYOND INNOVATION at Cphi Worldwide 2019, Booth No. 42C06
Conventional botulinum toxin products are in the form of syringes and are slow to perform their effect, PTx, one of Caregen's key products, has been developed into a cream and serum formulation and has a remarkable performance in 5 minutes.
Caregen is a Biotechnology company which manufactures and supplies functional cosmetics and cosmeceuticals like medical devices (fillers) based on the research and technology of Growth Factors and Peptides which acts just like Growth Factors. This technology-intensive enterprise develops and owns about 500 kinds of peptides with strong physiological activity and of these, 287 are registered as domestic and foreign patents.
Based on this technology, Caregen has achieved double-digit annual sales growth and industry-leading rate of operating profits. Dermaheal, Revofil and Prostrololane which are their own brands, are recognized abroad based on CE certification and they are exported to more than 130 countries which account for 90% of the total sales. In particular, in the M/S (market share) of the Russian and CIS filler markets, Caregen has been ranked 1st for several years.
Caregen is now preparing for a leap for greater growth. They have evolved from the small-scale framework of the sales structure of multi-product production system to a development of a product with high sales potential of blockbuster grade and is aiming to change the constitution from this year onwards.
One of their key products is PTx (Peptide Toxin), a peptide product that shows the mechanism of a botulinum toxin type C. PTx is a comprehensive product with Caregen’s know-how of Peptide development and it is the world's only cosmetic product with the mechanism of botulinum toxin. The existing botulinum toxin products are type A’s and they only cleave SNAP-25 of the snare complex within the neuron while PTx, a botulinum toxin type C product, is the world’s first product to show a strong mechanism of cleaving Syntaxin as well.
While the conventional botulinum toxin products are in the form of syringes and are slow to perform their effect, PTx has been developed into a cream and serum formulation and has a remarkable performance in 5 minutes. In addition, the advantage of PTx is that it exhibits variety of indications for typical botulinum toxins, including pain relief, hyperhidrosis, acne, sebum reduction and pore reduction, and Caregen has recently introduced a separate pain relief product called PTx Sports.
PTx sports is also a product of the cosmetics category, but has shown remarkable efficacy over medicines so it is effective to relieve from general muscle pains to chronic pains in 5 minutes. Since PTx sports is made of peptide components, it has additional advantages that it has no side effects on the body, has no smell or stickiness, and that it can be used easily.
Caregen is currently in deep discussions with many multinational companies in terms of licensing and distribution of PTx sports. Also, in preparation for the increase in demand, new investments for mass production are already under preparation and from the second half of next year, Caregen's production will more than triple.
In the meantime, the CEO of Caregen, Dr. Chung Yong Ji will present with the topic 'Topical Application of Botulinum Toxin Type C Peptide in Pharmaceutical and Aesthetic Applications' at 'Chpi Worldwide 2019' in Frankfurt on 11/5, 15:50 as the keynote speech for the seminar. You can also meet PTx from 11/5 - 11/7, Hall 4.2, 42C06 during the exhibition period.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...